A bupropion smoking cessation clinical trial for cancer patients

Cancer Causes and Control

Volumn 21, Issue 6, 2010, Pages 811-820

  Schnoll, Robert A ^a   Martinez, Elisa ^b   Tatum, Kristina L ^b   Weber, Dorothy M ^b   Kuzla, Natalie ^b   Glass, Marcella ^b   Ridge, John A ^b   Langer, Corey ^c   Miyamoto, Curtis ^d   Wileyto, E Paul ^a   Leone, Frank ^e  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b FOX CHASE CANCER CENTER   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d TEMPLE UNIVERSITY HOSPITAL   (United States)

^e PENN PRESBYTERIAN MEDICAL CENTER   (United States)

Author keywords

Bupropion; Cancer patients; Depression; Smoking

Indexed keywords

AMFEBUTAMONE; NICOTINE; PLACEBO;

ADULT; AFFECT; ARTICLE; CANCER PATIENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUNSELING; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; NICOTINE REPLACEMENT THERAPY; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; SEIZURE; SMOKING CESSATION; TOBACCO DEPENDENCE; TREATMENT OUTCOME; WITHDRAWAL SYNDROME;

ADMINISTRATION, CUTANEOUS; BUPROPION; DEPRESSION; DEPRESSIVE DISORDER; DOUBLE-BLIND METHOD; HUMANS; NEOPLASMS; NICOTINE; PATIENTS; PLACEBOS; PREVALENCE; SMOKING; SMOKING CESSATION; SUBSTANCE WITHDRAWAL SYNDROME; TREATMENT OUTCOME;

EID: 77955662373     PISSN: 09575243     EISSN: 15737225     Source Type: Journal    
DOI: 10.1007/s10552-010-9507-8     Document Type: Article

References (52)

1. Videtic GM, Stitt LW, Dar AR et al (2003) Continued cigarette smoking by patients receiving concurrent chemoradiotherapy for limited-stage small-cell lung cancer is associated with decreased survival. J Clin Oncl 21:1544-1549
2. Schnoll RA, James C, Malstrom M et al (2003) Longitudinal predictors of continued tobacco use among patients diagnosed with cancer. Ann Behav Med 25:214-222
3. Walker MS, Vidrine DJ, Gritz ER et al (2006) Smoking relapse during the first year after treatment for early-stage non-small-cell lung cancer. Cancer Epidemiol Biomarkers Prev 15:2370-2377
4. Zhou W, Heist RS, Liu G et al (2006) Smoking cessation before diagnosis and survival in early stage non-small cell lung cancer patients. Lung Cancer 53:375-380 (Pubitemid 44189564)
5. Garces YI, Schroeder DR, Nirelli LM et al (2007) Second primary tumors following tobacco dependence treatments among head and neck cancer patients. Am J Clin Oncol 30:531-539
6. Browman GP, Mohide EA, Willan A et al (2002) Association between smoking during radiotherapy and prognosis in head and neck cancer: a follow-up study. Head Neck 24:1031-1037
7. Carter CL, Key J, Marsh L et al (2001) Contemporary perspectives in tobacco cessation: what oncologists need to know. Oncologist 6:496-505
8. Tsao As, Liu D, Lee JJ, Sptiz M, Hong WK (2006) Smoking affects treatment outcome in patients with advanced nonsmall cell lung cancer. Cancer 106:2428-2436
9. Rades D, Setter C, Schild SE, Dunst J (2008) Effect of smoking during radiotherapy, respiratory insufficiency, and hemoglobin levels on outcome in patients irradiated for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 71:1134-1142
10. Vander Ark W, DiNardo LJ, Oliver DS (1997) Factors affecting smoking cessation in patients with head and neck cancer. Laryngoscope 107:888-892
11. Duarte RL, Luiz RR, Paschoal ME (2008) The cigarette burden (measured by the number of pack years smoked) negatively impacts the response rate to platinum-based chemotherapy in lung cancer patients. Lung Cancer 61:244-254
12. Baser S, Shannon VR, Eapen GA et al (2006) Smoking cessation after diagnosis of lung cancer is associated with a beneficial effect on performance status. Chest 130:1784-1790
13. Gritz ER, Fingeret MC, Vidrine DJ et al (2006) Successes and failures of the teachable moment: smoking cessation in cancer patients. Cancer 106:17-27
14. Gritz ER, Vidrine DJ, Fingeret MC (2007) Smoking cessation a critical component of medical management in chronic disease populations. Am J Prev Med 33:S414-S422
15. Gritz ER, Carr CR, Rapkin D et al (1993) Predictors of long-term smoking cessation in head and neck cancer patients. Cancer Epidemiol Biomarkers Prev 2:261-270
16. Schnoll RA, Zhang B, Rue M et al (2003) Brief physician-initiated quit-smoking strategies for clinical oncology settings: a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 21:355-365
17. Schnoll RA, Rothman RL, Wielt DB et al (2005) A randomized pilot study of cognitive-behavioral therapy versus basic health education for smoking cessation among cancer patients. Ann Behav Med 30:1-11
18. Schnoll RA, Malstrom M, James C et al (2002) Correlates of tobacco use among smokers and recent quitters diagnosed with cancer. Patient Educ Couns 46:137-145
19. Covey LS, Glassman AH, Stetner F (1990) Depression and depressive symptoms in smoking cessation. Compr Psychiatry 31:350-354 (Pubitemid 20333849)
20. Hayford KE, Patten CA, Rummans TA et al (1999) Efficacy of bupropion for smoking cessation in smokers with a former history of major depression or alcoholism. Br J Psychiatry 174:173-178
21. Hughes JR (1992) Tobacco withdrawal in self-quitters. J Consult Clin Psychol 60:689-697
22. Pirl WF (2004) Evidence report on the occurrence, assessment, and treatment of depression in cancer patients. J Natl Cancer Inst Monogr 32:32-39
23. van Wilgen CP, Dijkstra PU, Stewart RE et al (2006) Measuring somatic symptoms with the CES-D to assess depression in cancer patients after treatment: comparison among patients with oral/ oropharyngeal, gynecological, colorectal, and breast cancer. Psychosomatics 47:465-470
24. Lerman C, Roth D, Kaufmann V et al (2002) Mediating mechanisms for the impact of bupropion in smoking cessation treatment. Drug Alcohol Depend 67:219-223
25. Catley D, Harris KJ, Okuyemi KS et al (2005) The influence of depressive symptoms on smoking cessation among African Americans in a randomized trial of bupropion. Nicotine Tob Res 7:859-870
26. Hitsman B, Pingitore R, Spring B et al (1999) Antidepressant pharmacotherapy helps some cigarette smokers more than others. J Consult Clin Psychol 67:547-554
27. Sheehan DV, Lecrubier Y, Sheehan KH et al (1998) The Mini- International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59(Suppl 20):22-33
28. Martinez E, Tatum KL, Weber DM, et al (2009) Issues related to implementing a smoking cessation clinical trial for cancer patients. Cancer Causes Control 20:97-104
29. Radloff L (1977) The CES-D scale: a new self-report depression scale for research in the general population. Appl Psychol Meas 1:385-401
30. Heatherton TF, Kozlowski LT, Frecker RC et al (1991) The Fagerstrom test for nicotine dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br J Addict 86:1119-1127
31. de Graeff A, de Leeuw JR, Ros WJ et al (2000) Pretreatment factors predicting quality of life after treatment for head and neck cancer. Head Neck 22:398-407
32. Watson D, Clark LA, Tellegen A (1988) Development and validation of brief measures of positive and negative affect: the PANAS scales. J Pers Soc Psychol 54:1063-1070
33. Hughes JR, Hatsukami D (1986) Signs and symptoms of tobacco withdrawal. Arch Gen Psychiatry 43:289-294
34. Heil SH, Higgins ST, Mongeon JA et al (2006) Characterizing nicotine withdrawal in pregnant cigarette smokers. Exp Clin Psychopharmacol 14:165-170
35. Brown R, Burgess E, Sales S et al (1998) Reliability and validity of a smoking timeline follow-back interview. Psychol Addict Behav 12:101-112
36. Ware J Jr, Kosinski M, Keller SD (1996) A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity. Med Care 34:220-233
37. McCorkle R, Dowd M, Ercolano E, et al (2009) Effects of a nursing intervention on quality of life outcomes in postsurgical women with gynecological cancers. Psychooncology 18:62-70
38. Gandek B, Ware JE, Aaronson NK et al (1998) Cross-validation of item selection and scoring for the SF-12 Health Survey in nine countries: results from the IQOLA Project. International Quality of Life Assessment. J Clin Epidemiol 51:1171-1178
39. Fiore MC, Jaén CR, Baker TB, et al (2008) Treating tobacco use and dependence: 2008 update. Clinical Practice Guideline. Rockville, MD: U.S. Department of Health and Human Services, Public Health Service, May 2008
40. Glaxo-Wellcome (1999) Bupropion hydrochloride sustainedrelease tablets prescribing information. Research Triangle Park, North Carolina, USA
41. Holm KJ, Spencer CM (2000) Bupropion: a review of its use in the management of smoking cessation. Drugs 59:1007-1024
42. Jorenby DE, Leischow SJ, Nides MA et al (1999) A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 340:685-691
43. Cox LS, Patten CA, Niaura RS et al (2004) Efficacy of bupropion for relapse prevention in smokers with and without a past history of major depression. J Gen Intern Med 19:828-834
44. Hughes JR, Stead LF, Lancaster T (2007) Antidepressants for smoking cessation. Cochrane Database Syst Rev: CD000031
45. Rigotti NA, Munafo MR, Stead LF (2007) Interventions for smoking cessation in hospitalised patients. Cochrane Database Syst Rev: CD001837
46. Rigotti NA, Munafo MR, Stead LF (2008) Smoking cessation interventions for hospitalized smokers: a systematic review. Arch Intern Med 168:1950-1960
47. Shiffman S, Johnston JA, Khayrallah M et al (2000) The effect of bupropion on nicotine craving and withdrawal. Psychopharmacology (Berl) 148:33-40
48. Piper ME, Federmen EB, McCarthy DE et al (2008) Using mediational models to explore the nature of tobacco motivation and tobacco treatment effects. J Abnorm Psychol 117:94-105
49. Teneggi V, Tiffany ST, Squassante L et al (2005) Effect of sustained-release (SR) bupropion on craving and withdrawal in smokers deprived of cigarettes for 72 h. Psychopharmacology 183:1-12
50. Schnoll RA, Rothman RL, Lerman C et al (2004) Comparing cancer patients who enroll in a smoking cessation program at a Comprehensive Cancer Center with those who decline. Head Neck 26:278-286
51. Gonzales D, Rennard SI, Nides M et al (2006) Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs. sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 296:47-55
52. Dy SM, Lorenz KA, Naeim A et al (2008) Evidence-based recommendations for cancer fatigue, anorexia, depression, and dyspnea. J Clin Oncol 26:2886-2895